Brief Title
Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma
Official Title
Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma
Brief Summary
Study of the activity of PD-1 inhibitors in metastatic uveal melanoma
Detailed Description
The aim of the research is to study the activity of PD-1 inhibitors in patients with metastatic uveal melanoma and treated by Nivolumab and Pembrolizumab. These molecules have already received the authorities approvals. The data collected will be crucial for the understanding of the mechanism of PD-1 inhibitors and also for the futures studies.
Study Type
Observational
Primary Outcome
Response rate Data collection of the efficacity of PD-1 inhibitors
Secondary Outcome
Exploration of PD-1 inhibitors biomarkers
Condition
Uveal Melanoma
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
100
Start Date
November 2016
Completion Date
December 2019
Primary Completion Date
November 2019
Eligibility Criteria
Inclusion Criteria: - Patients with metastatic uveal melanoma - Patients who received at least once injection of Nivolumab or Pembrolizumab in the case of the disease's treatment Exclusion Criteria: - Antecedent of another evolutionary tumor pathology
Gender
All
Ages
N/A - N/A
Contacts
Manuel Rodrigues, MD, ,
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT03964298
Organization ID
IC-2016-05
Responsible Party
Sponsor
Study Sponsor
Institut Curie
Study Sponsor
Manuel Rodrigues, MD, Study Director, Institut Curie
Verification Date
October 2019